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Abstract
Purpose: NY-ESO-1 cancer testis (CT) antigen is an attractive candidate for immunotherapy as a result of its high
immunogenicity. The aim of this study was to explore the potential for NY-ESO-1 antigen directed immunotherapy in triple
negative breast cancer (TNBC) by determining the frequency of expression by immunohistochemistry (IHC) and the degree
of inherent immunogenicity to NY-ESO-1.
Experimental Design: 168 TNBC and 47 ER+/HER2- primary breast cancer specimens were used to determine NY-ESO-1
frequency by IHC. As previous studies have shown that patients with a robust innate humoral immune response to CT
antigens are more likely to develop CD8 T-cell responses to NY-ESO-1 peptides, we evaluated the degree to which patients
with NY-ESO-1 expression had inherent immunogenicity by measuring antibodies. The relationship between NY-ESO-1
expression and CD8+ T lymphocytes was also examined.
Results: The frequency of NY-ESO-1 expression in the TNBC cohort was 16% versus 2% in ER+/HER2- patients. A higher NY-
ESO-1 score was associated with a younger age at diagnosis in the TNBC patients with NY-ESO-1 expression (p=0.026). No
differences in OS (p=0.278) or PFS (p=0.238) by NY-ESO-1 expression status were detected. Antibody responses to NY-ESO-
1 were found in 73% of TNBC patients whose tumors were NY-ESO-1 positive. NY-ESO-1 positive patients had higher CD8
counts than negative patients (p=0.018).
Conclusion: NY-ESO-1 is expressed in a substantial subset of TNBC patients and leads to a high humoral immune response
in a large proportion of these individuals. Given these observations, patients with TNBC may benefit from targeted therapies
directed against NY-ESO-1.
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Introduction
Contemporary management of breast cancer with early
detection, newer local control techniques, improved chemotherapy
regimens, and targeted treatments has resulted in immense gains
in survival in individuals with breast cancer.[1] Unfortunately, the
triple negative breast cancers (TNBC) which are a subset of breast
cancers clinically defined by the absence of the estrogen receptor
(ER), progesterone receptor (PR), and Her 2 over expression, lack
a therapeutic target and have a poor prognosis. Compared with
non-TNBC, these lesions generally occur in younger women, are
of a higher grade, have a higher propensity to metastasize to
distant visceral organs, and have a worse outcome with a high rate
of recurrences after adjuvant treatments.[2] Thus, there is a dire
need to develop tumor-specific targets in an attempt to improve
the outcome for patients with TNBC. An attractive approach to
reduce the rate of recurrences in these individuals is use of
immunotherapeutic strategies which will be most efficient in the
state of minimal residual disease in individuals who have
completed standard surgery and adjuvant treatments. A pre-
requisite for the development of immune therapies is the
identification of immunogenic target cancer antigens.
Cancer testis (CT) antigens are encoded by a unique set of genes
that are predominantly expressed in human germ line cells and
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38783have minimal to no expression in somatic adult tissue. They
become abnormally activated in a variety of malignancies
including ovary, bladder, synovial sarcoma, lung, melanoma,
and breast cancer with over one hundred and fifty CT antigens
described.[3,4,5,6,7,8] The physiological function or prognostic
implication of most of the CT antigens remains unknown. NY-
ESO-1 is one of the more prominent CT antigens and is located
on the X-chromosome. It is found in a variety of tumors with
different histologic origins but not in normal tissues other than the
testis. NY-ESO-1 is believed to be one of the most immunogenic
CT antigens, inducing spontaneous humoral immunity in a subset
of patients whose tumors express this antigen.[9,10,11] As a result
of this property, NY-ESO-1 is an attractive candidate for
immunotherapy. Several early-phase clinical trials employing
NY-ESO-1 vaccines have demonstrated the ability of the vaccine
to induce T-cell and antibody mediated immuni-
ty.[12,13,14,15,16].
In this study, we analyzed the frequency of NY-ESO-1
expression in a large cohort of TNBC patient samples using
immunohistochemistry (IHC) and also examined NY-ESO-1
expression in relation to patient clinicopathologic characteristics
and degree of tumor infiltration by CD8+ T lymphocytes (TILs).
Because patients with robust humoral immunity to CT antigens
are more likely to have concomitant CD8 T-cell responses to NY-
ESO-1,[17] we evaluated the degree to which patients whose
tumors expressed NY-ESO-1 had inherent immunogenicity by
measuring humoral immunity to NY-ESO-1 and other CT
antigens. To our knowledge, this is the most comprehensive study
of CT antigens in TNBC.
Materials and Methods
Patients and Specimens
A total of 215 formalin-fixed paraffin embedded breast cancer
specimens were obtained from Roswell Park Cancer Institute
(RPCI) pathology resource network from patients who had been
treated between 1996 and 2010. For a subset of patients whose
tumors were found to express NY-ESO-1 by IHC, serum samples
were retrieved from the RPCI Data Bank and BioRepository
(DBBR). The DBBR, as previously described[18] is a compre-
hensive data and sample bank containing high quality biospeci-
mens obtained prior to surgery and treatment from patients who
provided informed consent, as well as associated clinical and
epidemiologic data. Medical records were retrospectively reviewed
on all patients for details of the clinicopathologic characteristics of
the diagnosed cancer, including information on clinical outcome.
The duration of overall survival (OS) was defined as the time
period between diagnosis and death, while progression-free
survival (PFS) was the time between diagnosis and evidence of
clinical progression or death. Data were censored at time of last
follow-up for those patients without an event.
Ethics Statement
The study was conducted under approval from the RPCI
Institutional Review Board.
IHC
The methods for determining NY-ESO-1 expression from
formalin-fixed paraffin sections have been previously de-
scribed.[19,20] In brief, paraffin sections were cut at 5 mm, placed
on charged slides and dried in a 60uC oven for 1 hour. Room
temperature slides were then deparaffinized in xylene and
rehydrated using graded alcohols. Endogenous peroxidase was
then quenched with aqueous hydrogen peroxidize and washed
with phosphate buffered saline tween (PBS/T). Antigen retrieval
was then performed in the microwave in Target Retrieval Solution
(Dako), with a cool down period, followed by a PBS/T wash.
Slides were then loaded on the DAKO autostainer and the
following program was run: Casein 0.03% (in PBS/T) was used to
block for 30 minutes, blown off, and the primary antibody NY-
ESO-1 (Zymed/Invitrogen mouse monoclonal) applied at 5 mg/
ml to slides for one hour. A PBS/T wash was followed by mouse
Envision+ Polymer (Dako). PBS/T was then used as a wash and
the chromagen DAB+ (Dako) applied for 10 minutes. The slides
were then counterstained with hematoxylin, dehydrated, cleared,
and coverslipped. Antigen expression was scored by a trained
pathologist (WB) and was categorized based on the percentage
staining (0%, ,10%, 10–50%, .50%) and intensity (0, 1, 2, 3) of
the tumor cell population. Methods used to determine CD8 testing
by IHC have been described previously.[12] Each entire tumor
section was evaluated for tumor infiltrating lymphocytes (TILs) by
using X20 objective lens, and 10 independent areas with the most
abundant TILs selected, digitally photographed at a size of
0.0625 mm
2, and counted manually. The count was performed 2
times for each photograph by the same pathologist without
knowledge of the earlier result. The average TIL count for each
patient was used for statistical analysis. The average CD8 count
per 1 mm
2 was computed.
Detection of CT Antibodies by ELISA
Human sera samples which had been stored in liquid nitrogen
vapor were obtained from the RPCI DBBR for a subset of
patients. Antibodies to NY-ESO-1 and other CT antigens were
detected by ELISA as described previously.[21].
Table 1. Patient characteristics.
TNBC ER+/HER2- p value
N% N %
All samples 168 100 47 100
Age at
diagnosis
Mean (SD) 52.9 (13) 58.4 (15.4)
Race White 117 70 45 96 ,.001
Black 47 28 2 4
Grade 1 3 2 6 13 ,.001
2–3 160 95 29 62
Histology Ductal 151 90 29 62 ,.001
Lobular 7 4 9 19
Other 10 6 9 19
Stage
1 11 1 - - ,.001
21 0 9 6 5 - -
35 6 3 3 4 3 9 1
41 1 4 9
Tumor size
1 Mean (SD) 3.3 (2.3) 4.0 (2.5) .025
LVI
2 No 69 49 9 43 .645
Yes 71 51 12 57
1These are not accurate reflections of the differences between TNBC and ER+/
HER2- due to the sampling method.
2LVI is lymphovascular invasion.
doi:10.1371/journal.pone.0038783.t001
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Hypomethylation
MCF-7 breast cancer cell line (originally procured from
American Type Culture Collection, Manassas, VA) was a gift
from Dr. Gokul Das (Department of Pharmacology and Thera-
peutics, RPCI). The cell line was grown in the recommended
media under standard conditions. Cells were treated with either
Decitabine (DAC, 5-aza-29-deoxycytidine, Sigma-Aldrich Corp,
St. Louis, MO) at 0.1, 0.5, or 1 mM or Vidaza (5-azacytidine,
Sigma-Aldrich Corp, St. Louis, MO) at 1 or 2 mM. Cells were
treated twice at 0 and 48 hours, and RNA and DNA were
extracted at 72 hours for analyses. Total RNA was extracted using
Trizol (Invitrogen, Carlsbad, CA) and cDNA synthesis was carried
out with iscript cDNA synthesis kit (Biorad, Hercules, CA). NY-
ESO-1 was amplified using the following primers: F
59GGCTGAATGGATGCTGCAGA39and R 59 CGGACA-
CAGTGAA CTCCTTC-39 for 35 cycles at 60uC. GAPDH was
amplified as a control for equal cDNA input. With regards to
sodium bisulfite DNA pyrosequencing, briefly, DNA was isolated
using Puregene core kit A (Qiagen, Valencia, CA). EZ DNA
methylation kit (Zymo Research Corp, Irvine, CA) was used to
bisulfite convert 1 ug of DNA according to the manufacturer’s
recommendations. Quantitative pyrosequencing of NY-ESO-1
Figure 1. NY-ESO-1 expression by IHC compared with a negative IgG control. Photomicrograph of NY-ESO-1 expression by
immunohistochemistry side by side compared with a negative IgG control.
doi:10.1371/journal.pone.0038783.g001
Table 2. NY-ESO-1 expression frequency by IHC.
Expression TNBC ER+/HER2-
N (168) % N (47) %
Intensity
3+ 11 7 0 -
2+ 10 6 1 2
1+ 630 -
Total positive 27 16 1 2
Total negative 141 84 46 98
Percent staining
,10% 13 8 1 2
10–50% 5 3 0 -
.50% 9 5 0 -
Total positive 27 16 1 2
Total negative 141 84 46 98
doi:10.1371/journal.pone.0038783.t002
Figure 2. OS by NY-ESO-1 expression in TNBC. Kaplan-Meier
curve showing OS differences in patients with TNBC stratified by NY-
ESO-1 expression.
doi:10.1371/journal.pone.0038783.g002
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Valencia, CA). The primers used for amplification and sequencing
of NY-ESO-1 and the conditions used were as previously
described.[22].
Statistical Analyses
The categorical variables were summarized using frequencies
and relative frequencies. Fisher’s exact test used to study the
association between categorical variables and TNBC status.
Numerical variables were summarized using means and standard
deviations, with the Wilcoxon exact test used compare numerical
variables between TNBC groups. For those patients with NY-
ESO-1 expression, a score (1–9) was calculated as intensity (1=
,10%, 2=10%–50% and 3= .50%) times expression (1=1+,
2=2+ and 3=3+). The association between this NY-ESO-1 score
and patient demographics was assessed using univariate regression
models, with the NY-ESO-1 score as the response and the
demographic variables as predictors. Diagnostic plots were used to
assess all model assumptions. The Kruskal Wallis exact test was
used to compare the CD8 counts between the minimum,
moderate, and brisk infiltrate groups for both the NYESO-1
positive and negative patients. The Wilcoxon exact test was used
to compare the CD8 counts between the NYESO-1 positive and
negative patients. The overall and progression free survival times
were summarized using Kaplan-Meier methodology, with the
Log-rank test used to compare the survival distributions between
patient groups. All analysis was conducted in SAS v9.2 (Cary, NC)
with a nominal significance level of 0.05.
Results
Study Population
Two hundred and fifteen (168 TNBC and 47 ER+/HER2-)
primary breast cancer patients’ specimens were used to determine
the frequency of NY-ESO-1 CT antigen by IHC. ER+/HER2-
tumors were used as a comparison to avoid the potential for
confounding by HER+ status. We initially planned to select
patients with more advanced stage and/or higher grade tumors
where one would expect NY-ESO-1 to be positive based on the
literature. However, in order to achieve the required sample size of
TNBC patients, we had to include a large number of those cases
with earlier stage disease. The ER+/HER2- cases were left as
more advanced stage due to the availability of sufficient patient
samples with this subtype. Table 1 shows the patient character-
istics of the entire cohort. As expected, TNBC patients were more
likely to be younger (p=0.030), black (p,0.001), have ductal
histology (p,0.001), and higher grade tumors (p,0.001) than
patients with ER+ breast cancer despite the higher proportion of
advanced stages in the ER+ patients due to the sampling method.
NY-ESO-1 Expression
To avoid the problem of tumor heterogeneity, whole sections
were used to determine the frequency of NY-ESO-1 expression by
IHC. Figure 1 shows a positively staining tumor in comparison
with a negative control. In the entire breast cancer cohort, the
frequency of NY-ESO-1 expression was 13%. In TNBC it was
16%, and just 2% in ER+ (Table 2). Most of the tumors expressing
NY-ESO-1 positivity were either 2 or 3+ in intensity, but ,10% in
percentage staining. We also calculated a score of 0–9 which was a
combination of the intensity and percent staining and found a
significant association between intensity and percent in those who
expressed NY-ESO-1.
In the 27 TNBC patients with NY-ESO-1 expression, we found
that a higher NY-ESO-1 score was associated with a younger age
at diagnosis (p=0.026). There was no significant relationship
between presence of lymphovascular space invasion, histology,
stage, grade, tumor size, number of involved lymph nodes, or race.
Figure 3. PFS by NY-ESO-1 expression in TNBC. Kaplan-Meier
curve showing PFS differences in patients with TNBC stratified by NY-
ESO-1 expression.
doi:10.1371/journal.pone.0038783.g003
Table 3. Characteristics of NY-ESO-1 positive TNBC patients with NY-ESO-1 antibodies.
Patient ID
Age at
diagnosis Stage Grade Recurrence
Status at last
follow up
Disease free interval
in weeks
1 60 lllA T2 N2 M0 3 NONE, DISEASE FREE ALIVE 351
2 41 IIA T1 N1 M0 3 NONE, DISEASE FREE ALIVE 279
3 49 lllC T1 N3 M0 3 NONE, DISEASE FREE ALIVE 292
4 56 IIA T2 N0 M0 3 NONE, DISEASE FREE ALIVE 247
5 50 IIA T2 N0 M0 3 NONE, DISEASE FREE ALIVE 165
6 40 IIB T2 N1 M0 3 NONE, DISEASE FREE ALIVE 241
7 56 IIA T2 N0 M0 3 NONE, DISEASE FREE DEAD (pancreas cancer) 50
8 39 IIB T2 N1 M0 3 NONE, DISEASE FREE ALIVE 301
doi:10.1371/journal.pone.0038783.t003
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(p=0.278) or PFS (p=0.238) by NY-ESO-1 expression status
(Figures 2 & 3). Only 6 deaths (all within 2 years) occurred out of
27 TNBC patients with expression and 51 deaths out of 141
TNBC patients whose tumors did not express NY-ESO-1. Patients
had a similar 2 year OS rate of 77% (95% CI: 56–89%) vs 80%
(95% CI: 73–86%). Similar results were found for PFS.
Analysis of Immune Response to NY-ESO-1 CT Antigen in
TNBC
Eleven of 27 NY-ESO-1 expressing TNBC patients had pre-
therapy serum samples available to assess for antibody responses.
Antibodies against NY-ESO-1, LAGE-1, several other CT antigens
(MAGE-A1, MAGE-A3, p53, DHFR, MAGE-A4, MAGE-A10,
SSX-1, SSX-2, SSX-4, SOX2, CT7, CT10, CT45, CT46, CT47,
XAGE-1, PLAC1 MELAN-A, GAGE-2/7, CT55, CT63,
TRAG3/CT24, ERG, CT39, CT14, CT57), Melan-A, and
UBQLN2 were investigated. Antibody responses to NY-ESO-1
were found in 8 of 11 (72.7%) TNBC patients whose tumors were
NY-ESO-1 positive by IHC. A similarly high proportion, (7 of 11;
64%) demonstrated spontaneous antibody response to LAGE-1,
whichhasa94%homologytoNY-ESO-1.[23]Tables3and4show
the characteristics of TNBC patients with and without an immune
response to NY-ESO-1 CT antigen. The mean disease free interval
was similar between the patients whose sera had NY-ESO-1
antibodies versus the group of patients that did not have innate
antibody responses (240 versus 284 weeks). The only other antigen
thathadasubstantialproportionofantibodiesdetectedwasp53CT
antigen; 4 of 11 (36.4%) patients. Antibody responses to the other
antigens were infrequent ranging from 0 to 18%.
NY-ESO-1 Expression and CD8 Tumor Infiltrating
Lymphocytes (TILs)
To test whether NY-ESO-1 expression predicts infiltration by
CD8+ TILs, we examined the relationship between NY-ESO-1
expression and CD8+ TILs. The CD8 count was calculated by
dividing of the number of CD8 positive cells by the area of
analysis. A minimal, moderate, or brisk CD8 infiltrate was
characterized as 0–5, 6–50, or .50 cells/high power field
respectively.[9] Figure 4 demonstrates the extent of CD8
infiltration in triple negative breast specimens. Among the 27
TNBC patients whose tumors were NY-ESO-1 positive by IHC,
the median CD8 count was 358.5cells/mm
2 (range 0.9 to
1601.1cells/mm
2). Seventeen of these 27 patients (63%) had a
brisk CD8 infiltrate, while a moderate or minimal infiltrate was
observed in 7 (26%) and 3 (11%) respectively. Among an age- and
stage-matched cohort of 28 TNBC patients without NY-ESO-1
expression, the median CD8 count was 98.7cells/mm
2 (range 0 to
828.7 cells/mm
2). 10 of these 28 patients (36%) had a brisk CD8
infiltrate, while a moderate or minimal infiltrate was observed in
12 (43%) and 6 (21%) respectively. Figure 5 shows the relationship
between NY-ESO-1 expression and degree of CD8 tumor
infiltrating lymphocytes in TNBC.
The NY-ESO-1 positive patients tended to have higher CD8
counts (mean/SD: 428.1 cells/mm
2/419) versus the negative
patients (mean/SD: 195.7 cells/mm
2/217) [p=0.018]. Although,
it did not reach statistically significance, there was a positive
correlation between NY-ESO-1 antibody density and CD8 count
in the 8 patients whose sera was positive for NY-ESO-1 antibodies
(p=0.068).
Table 4. Characteristics of NY-ESO-1 positive TNBC patients without NY-ESO-1 antibodies.
Patient ID Age at diagnosis Stage Grade Recurrence
Status at last
follow up
Disease free
interval in weeks
9 44 IIB T2 N0 M0 3 NONE, DISEASE FREE ALIVE 217
10 45 IIA T2 N0 M0 2 NONE, DISEASE FREE ALIVE 552
11 73 IIIA T2 N2 M0 3 NONE, DISEASE FREE ALIVE 83
doi:10.1371/journal.pone.0038783.t004
Figure 4. Extent of CD8 infiltration in triple negative tumors. This figure demonstrates the extent of CD8 infiltration in triple negative breast
specimens.
doi:10.1371/journal.pone.0038783.g004
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As CT antigens are regulated by DNA methylation,[24] we
determined the ability to induce NY-ESO-1 expression in vitro by
treating MCF-7 breast cancer cell lines with hypomethylating
agents (decitabine and 5-azacytidine) at 0 and 48 hours. DNA and
RNA were extracted for analyses at 72 hours. Figure 6 shows the
effective induction of NY-ESO-1 by both agents. In addition,
quantitative pyrosequencing of NY-ESO-1 promoter showed that
the percentage of NY-ESO-1 promoter methylation was reduced
by both decitabine and 5-azacytidine in MCF-7 cells (Figure 7).
Discussion
Therapeutic options for individuals with TNBC remain limited.
In addition, the clinical outcome of these patients is poorer than
the outcome of those with hormone receptor positive breast
cancer. Due to that fact that tumors express specific antigens that
can be recognized by T-cells,[25,26] anti-cancer vaccines may
have a role to play in management of these patients if an
appropriate target antigen and patient population can be
identified. Due to its high degree of immunogenicity, NY-ESO-1
has emerged as one of the important targets for immunotherapy.
Although, a number of studies have sought to determine the
frequency of NY-ESO-1 expression in primary breast cancers,
several of them have been flawed as they have not selected patients
based on hormone or HER2 receptor sta-
tus.[5,9,20,27,28,29,30,31] The current study represents the
largest and most rigorous investigation on NY-ESO-1 CT antigen
in patients with TNBC. In addition, while a number of clinical
trials utilizing various forms of vaccines against NY-ESO-1 have
been completed, no specific breast cancer trial using this strategy
has been implemented. Our results show that NY-ESO-1 CT
antigen can be detected by IHC in up to 16% of TNBC patients,
as opposed to only 2% of patients with hormone receptor positive
disease and thus is a valid target for immunotherapy in the TNBC
sub-group of patients.
A limitation of our study was the inclusion of 66% of the TNBC
cohort having earlier stages (1/2) of cancer vs. the comparison
ER+ group without any stage 1 or 2 patients. This may have
resulted in a bias in the results as, theoretically, early stage of
disease may have higher rates of NY-ESO-1 expression or other
immune responses before host immune tolerance to tumor is
established. When tumor grows or disease progresses, host
immune tolerance to tumor antigens start to be established due
to immunosuppressive mechanism such as induction of immuno-
suppressive cell populations and cytokines, and immune check-
points. Thus, expression of tumor antigen or immune response
may potentially be down regulated during a later stage of disease.
Our data did not suggest any relationship between clinical
outcome and NY-ESO-1 antigen expression, or antibody
response. While this may be due to the low event rate in our
cohort, it is also possible that CT antigen expression has a neutral
effect on breast cancer prognosis as also reported for ovarian
cancer.
19 Nevertheless, the NY-ESO-1 positive patients tended to
have higher tumor infiltration by CD8+ T cells, and those with
Figure 5. The relationship between NY-ESO-1 expression and
degree of CD8 tumor infiltrating lymphocytes in TNBC. This
figure shows the relationship between NY-ESO-1 expression and degree
of CD8 tumor infiltrating lymphocytes in TNBC.
doi:10.1371/journal.pone.0038783.g005
Figure 6. Induction of NY-ESO-1 by decitabine and 5-azacytidine. Photomicrograph showing the ability of decitabine and 5-azacytidine to
induce of NY-ESO-1 in vitro in MCF-7 cells.
doi:10.1371/journal.pone.0038783.g006
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T cells, indicating a potential link between NY-ESO-1 immunity
and infiltration of TNBC by T cells. This is an important
consideration as the presence of intratumoral T cells has been
shown to correlate with improved survival in patients with several
cancer types such as ovarian, colon, lung, melanoma, and breast
cancers.[32,33,34,35,36,37] Moreover, tumor infiltrating lympho-
cytes have been shown to predict response to anthracycline-based
chemotherapy in estrogen receptor-negative breast cancer.[38].
We also showed that induction of expression of NY-ESO-1 in
vitro using hypomethylating agents is feasible. This could be of
considerable clinical significance as it may be reasonable to
hypothesize that induction of NY-ESO-1 in vivo utilizing a similar
strategy is possible. In fact, a recently published phase I trial of
decitabine with carboplatin in ovary cancer patients showed DNA
hypomethylating activity with a decitabine-based regimen.[39]
Several other clinical trials employing a similar strategy of
hypomethylation or other epigenetic modulation to re-express
‘silenced’ hormone receptors or tumor suppressor genes in breast
carcinomas are underway. The question as to whether inducing
NY-ESO-1 in vivo will augment spontaneous or vaccine induced
immunity to NY-ESO-1 requires further investigation.
The high frequency of 73% of NY-ESO-1 antibodies in NY-
ESO-1 expressing TNBC patients in this present study was
unexpected. Although surprising, these findings are however
accurate given the similar high antibody frequency also observed
in the close homolog, LAGE-1. Other studies showed that
antibodies to NY-ESO-1 were demonstrable in 0.9% to 4% of
unselected primary breast cancer patients’ sera.[7,8,27] Hamaı ¨ et
al. showed that 12 of 1374 (0.9%) primary unselected breast
cancer patients had detectable antibodies to NY-ESO-1. Of those
who had tissue available, 7 of 8 (88%) were found to be NY-ESO-
1 positive by PCR, and had high-grade ER negative disease. The
patient whose breast cancer was NY-ESO-1 negative was
diagnosed with melanoma very soon afterwards. This suggests
that the development of an immune response to NY-ESO-1 is
specific to those whose tumors are positive for the antigen and may
be found in a higher proportion of properly selected patients.
Other studies in ovary cancer have shown antibody rates of up to
12.5% to 30% in patients with NY-ESO-1 positive tumors.[19,40]
This study by Stockert et al. showed a frequency of up to 50% in
patients with more advanced NY-ESO-1 expressing tumors.
The implications of our findings are twofold. First, these results
suggest that the subset of patients with TNBC whose tumors
express NY-ESO-1 have particularly high inherent immunoge-
nicity and therefore are an attractive population for CT vaccine
studies. A spontaneous antibody response to NY-ESO-1 antigen
has been shown to predict both CD8 and CD4 T cell response to
NY-ESO-1.[17,41] This will imply a possible clinical benefit given
that CD8 T cells are critical in tumor rejection.[42] The other
ramification of these results is the possibility of utilizing an NY-
ESO-1 vaccine strategy in patients with TNBC to boost any
preexisting immunity to NY-ESO-1. This will likely assist with T
cell expansion/activation and the potential for co-stimulatory
blockade of negative immune regulatory factors and subsequently
the induction of improved host tumor rejection. In addition to T
cell receptor recognition, the optimal activation of a T cell involves
signals provided by co-stimulatory molecules which are balanced
by negative co-stimulatory molecules. It is clear that several factors
including cytotoxic lymphocyte antigen–4:B7 (CTLA-4:B7),[43]
programmed death-1 (PD-1),[44,45] and lymphocyte activation
gene-3 (LAG 3) all negatively regulate T cell activation. For
example, PD-LI, the ligand for PD-1 is expressed in up to 50% of
invasive ductal carcinomas and is associated with worse prognostic
indices.[46] Grosso et al. showed that LAG 3 blockade resulted in
increased accumulation and function of antigen-specific CD8 T
cells within organs and tumors that express their cognate antigen.
In addition, combining LAG 3 blockade with specific antitumor
vaccines resulted in an increase in activated CD8 T cells in the
tumor and disruption of the tumor parenchyma.[47] Similarly,
ipilimumab, a monoclonal antibody against CTLA-4 also utilized
as a therapy for patients with malignant melanoma has been
shown to result in the most clinical benefit in patients with pre-
existing NY-ESO-1 immunity.[48] Together, targeting negative T
cell co-stimulatory pathways with immunotherapy directed against
NY-ESO-1 in patients with TNBC may be a novel way to
ultimately improve clinical outcomes for this subset of patients.
In conclusion, our study reveals that NY-ESO-1 is expressed in
a subset of TNBC patients and leads to a relatively high
spontaneous humoral immune response rate in these individuals.
Although the influence of NY-ESO-1 positivity on the OS or PFS
Figure 7. NY-ESO-1 promoter methylation was reduced by both decitabine and 5-azacytidine in MCF-7 cells. Graph showing that NY-
ESO-1 promoter methylation was reduced by both decitabine and 5-azacytidine in MCF-7 cells.
doi:10.1371/journal.pone.0038783.g007
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38783of TNBC patients is likely neutral as evidenced by this present
study, the potential for augmenting an individual’s immunity by
interfering with negative T cell co-stimulatory pathways is worthy
of further investigation. Given these observations, we propose that
patients with TNBC may benefit from targeted therapies directed
against NY-ESO-1.
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